Reading a Tumor's genetic signature to outsmart head and neck cancer
NCT ID NCT06725342
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study analyzes DNA and RNA from stored tumor samples of 401 people with head and neck squamous cell carcinoma. The goal is to classify each tumor by its genetic mutations and immune activity, potentially pointing toward which treatments—such as immunotherapy—might work best. No new drugs are being tested; instead, researchers aim to build a molecular roadmap for smarter treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this approach could help doctors select the most effective treatments for each patient based on their tumor's genetic and immune profile.
- What could go wrong
- This is an observational, lab-based study, not a treatment trial. The classification system may not translate into better outcomes until tested in future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?